Mauna Kea Technologies commercializes Cellvizio, a probe-based confocal laser endomicroscopy system that allows physicians to obtain real-time cellular images inside the body during procedures. The company is focusing on accelerating commercial momentum as adoption of Cellvizio grows worldwide. Following a court-approved safeguard plan, Mauna Kea reduced gross debt from €40 million to €12 million and increased equity by €7.7 million, materially improving its balance sheet. Remaining debt will be amortized over ten years, with most repayments scheduled between 2029 and 2035, giving the firm flexibility to pursue sales expansion and work toward profitability. With the recent capital raise, management projects a cash runway extending into the second half of 2027. The company plans to prioritize commercial execution and shareholder-aligned value creation initiatives, including the free allotment of warrants announced alongside the restructuring.

Total raised

$7M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025